Q3 EPS Estimates for MiNK Therapeutics Reduced by B. Riley

Key Points

• B. Riley has lowered its Q3 2025 earnings per share estimate for MiNK Therapeutics from ($0.71) to ($0.91), while maintaining a "Strong-Buy" rating on the stock.
• MiNK Therapeutics recently faced mixed reviews from analysts, including a downgrade from Zacks Research to a "strong sell" and an upgrade from HC Wainwright to a "buy" with a price target of $35.00.
• The company's stock has shown volatility, with a 12-month price range of $4.56 to $76.00 and a recent opening price of $14.95.

MiNK Therapeutics, Inc. (NASDAQ:INKT - Free Report) - Investment analysts at B. Riley decreased their Q3 2025 earnings per share (EPS) estimates for shares of MiNK Therapeutics in a report issued on Wednesday, August 20th. B. Riley analyst M. Mamtani now expects that the company will post earnings per share of ($0.91) for the quarter, down from their previous forecast of ($0.71). B. Riley has a "Strong-Buy" rating on the stock. The consensus estimate for MiNK Therapeutics' current full-year earnings is ($2.75) per share. B. Riley also issued estimates for MiNK Therapeutics' Q4 2025 earnings at ($0.96) EPS, FY2025 earnings at ($3.58) EPS, FY2026 earnings at ($4.17) EPS, FY2027 earnings at ($4.63) EPS, FY2028 earnings at $5.00 EPS and FY2029 earnings at ($5.43) EPS.

MiNK Therapeutics (NASDAQ:INKT - Get Free Report) last posted its quarterly earnings data on Thursday, August 14th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.55) by ($0.51).

INKT has been the topic of several other reports. Wall Street Zen lowered MiNK Therapeutics to a "strong sell" rating in a research note on Saturday. William Blair cut MiNK Therapeutics from an "outperform" rating to a "market perform" rating in a report on Friday, July 11th. HC Wainwright upgraded MiNK Therapeutics from a "neutral" rating to a "buy" rating and set a $35.00 price target on the stock in a research report on Friday, August 15th. Finally, Zacks Research cut MiNK Therapeutics from a "hold" rating to a "strong sell" rating in a research note on Monday, August 18th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $37.50.

MiNK Therapeutics Stock Up 1.0%

Shares of INKT stock traded up $0.15 during mid-day trading on Friday, reaching $15.30. 24,095 shares of the stock traded hands, compared to its average volume of 397,621. The stock's fifty day simple moving average is $14.95 and its two-hundred day simple moving average is $10.47. The company has a market cap of $69.16 million, a price-to-earnings ratio of -5.29 and a beta of 0.33. MiNK Therapeutics has a 1-year low of $4.56 and a 1-year high of $76.00.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials.